MedWatch

Analyst: This will be crucial to Novo’s haemophilia drug

The latest data from a phase III study with Novo Nordisk’s haemophilia drug N9-GP are highly positive, says analyst Søren Løntoft Hansen and points out one factor that will determine the success of the drug on an extremely conservative market.

Foto: Novo Nordisk/PR

It is positive news for Novo, says analyst Søren Løntoft Hansen, Sydbank, about last week’s publication of data from a phase III study with company’s drug against haemophilia B, N9-GP.

“Compared with haemophilia A, however, haemophilia B is rarer, meaning the population is also smaller. Moreover, the market is conservative and a switch from one drug to another is less common than seen elsewhere,” he explains to Medwatch and adds:

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier